JAZZ PHARMACEUTICALS PLC (1JAZZ.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1JAZZ - IE00B4Q5ZN47 - Common Stock
1JAZZ.MI Key Statistics, Chart & Performance
The current stock price of 1JAZZ.MI is 147.15 EUR.
1JAZZ.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 10.89 | 201.00B | ||
| SNW.DE | SANOFI | 10.88 | 200.78B | ||
| 1SAN.MI | SANOFI | 10.69 | 197.40B | ||
| MRK.DE | MERCK KGAA | 14.93 | 55.37B | ||
| UCB.BR | UCB SA | 39.89 | 49.81B | ||
| UNC.DE | UCB SA | 39.36 | 49.15B | ||
| 1BAYN.MI | BAYER AG-REG | 7.12 | 37.38B | ||
| BAYN.DE | BAYER AG-REG | 7.18 | 37.67B | ||
| IPN.PA | IPSEN | 11.85 | 10.20B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 108.89 | 10.08B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.5 | 10.09B | ||
| VIRP.PA | VIRBAC SA | 20.7 | 3.01B |
Related stock screener links
About 1JAZZ.MI
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Company Info
JAZZ PHARMACEUTICALS PLC
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4
DUBLIN DUBLIN IE
Employees: 2800
Phone: 35316347800
JAZZ PHARMACEUTICALS PLC / 1JAZZ.MI FAQ
What does JAZZ PHARMACEUTICALS PLC do?
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Can you provide the latest stock price for JAZZ PHARMACEUTICALS PLC?
The current stock price of 1JAZZ.MI is 147.15 EUR. The price increased by 13.24% in the last trading session.
Does 1JAZZ stock pay dividends?
1JAZZ.MI does not pay a dividend.
What is the ChartMill rating of JAZZ PHARMACEUTICALS PLC stock?
1JAZZ.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does JAZZ PHARMACEUTICALS PLC (1JAZZ.MI) report earnings?
JAZZ PHARMACEUTICALS PLC (1JAZZ.MI) will report earnings on 2026-02-23, after the market close.
1JAZZ.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1JAZZ.MI.
1JAZZ.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1JAZZ.MI. Both the profitability and financial health of 1JAZZ.MI have multiple concerns.
1JAZZ.MI Financial Highlights
Over the last trailing twelve months 1JAZZ.MI reported a non-GAAP Earnings per Share(EPS) of 6.94. The EPS decreased by -58.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| Debt/Equity | 1.09 |
1JAZZ.MI Forecast & Estimates
24 analysts have analysed 1JAZZ.MI and the average price target is 179.81 EUR. This implies a price increase of 22.19% is expected in the next year compared to the current price of 147.15.
For the next year, analysts expect an EPS growth of -61.13% and a revenue growth 4.61% for 1JAZZ.MI